Clinical Trial Update: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) [Phase 2, Phase 3]

View source ↗

Summary

This document reports a Phase 2/3 clinical trial evaluating the combination of Livmoniplimab and Budigalimab in adults with hepatocellular carcinoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Livmoniplimab
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: RECRUITING